
TY  - JOUR
AU  - Lloyd, Geoff
AU  - Friedman, Gary
AU  - Jafri, Syed
AU  - Schultz, Greg
AU  - Fridman, Alex
AU  - Harding, Keith
TI  - Gas Plasma: Medical Uses and Developments in Wound Care
JO  - Plasma Processes and Polymers
JA  - Plasma Processes Polym.
VL  - 7
IS  - 3‐4
SN  - 1612-8850
UR  - https://doi.org/10.1002/ppap.200900097
DO  - doi:10.1002/ppap.200900097
SP  - 194
EP  - 211
KW  - atmospheric plasmas
KW  - bacterial destruction
KW  - decontamination of wounds
KW  - interaction of plasma with living tissue
KW  - non-thermal gas plasmas (NTGPs)
PY  - 2010
AB  - Abstract Non-thermal gas plasmas (NTGPs) are a promising emergent medical technology.a Unlike thermal plasmas, they generate a complex room temperature mix of reactive species which interact with tissues. The characterization of candidate plasmas and their interaction with tissues has shown that they produce a variety of broadly dose dependent effects ranging from fibroblast proliferation to angiogenesis and bacterial destruction. These findings, supported by recent experiments using skin models, suggest that NTGP's could potentially play an important role in both decontaminating acute and chronic wounds and accelerating healing. However, important issues over toxicological and environmental safety remain unanswered and a number of regulatory and technical hurdles will need to be overcome before a NTGP medical device is released.
ER  - 

TY  - JOUR
TI  - ASBMR 29th Annual Meeting
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 22
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650221405
DO  - doi:10.1002/jbmr.5650221405
SP  - s152
EP  - s201
PY  - 2007
ER  - 

TY  - JOUR
TI  - 115Th annual meeting of the American Neurological Association. Abstracts
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 28
IS  - 2
SN  - 0364-5134
UR  - https://doi.org/10.1002/ana.410280229
DO  - doi:10.1002/ana.410280229
SP  - 218
EP  - 284
PY  - 1990
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 16
IS  - S3
SN  - 1600-6135
UR  - https://doi.org/10.1111/ajt.13898
DO  - doi:10.1111/ajt.13898
SP  - 405
EP  - 798
PY  - 2016
ER  - 

TY  - JOUR
TI  - Official Proceedings 37th Annual Convention
JO  - Journal of Ultrasound in Medicine
VL  - 12
IS  - 3
SN  - 0278-4297
UR  - https://doi.org/10.7863/jum.1993.12.3.1
DO  - doi:10.7863/jum.1993.12.3.1
SP  - 1
EP  - 92
PY  - 1993
ER  - 

TY  - JOUR
AU  - TRIPODI, A.
AU  - ANSTEE, Q. M.
AU  - SOGAARD, K. K.
AU  - PRIMIGNANI, M.
AU  - VALLA, D. C.
TI  - Hypercoagulability in cirrhosis: causes and consequences1
JO  - Journal of Thrombosis and Haemostasis
VL  - 9
IS  - 9
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2011.04429.x
DO  - doi:10.1111/j.1538-7836.2011.04429.x
SP  - 1713
EP  - 1723
KW  - chronic liver disease
KW  - factor VIII
KW  - protein C
KW  - thrombin
KW  - thrombomodulin
PY  - 2011
AB  - Summary.? Decreased levels of most coagulation factors and thrombocytopenia are the main haemostatic abnormalities of cirrhosis. As a consequence, this condition was, until recently, considered as the prototype acquired coagulopathy responsible for bleeding. However, recent evidence suggests that it should, rather, be regarded as a condition associated with normal or even increased thrombin generation. The bleeding events that occur in these patients should, therefore, be explained by the superimposed conditions that frequently occur in this setting. Due to elevated levels of factor VIII (procoagulant driver) in combination with decreased protein C (anticoagulant driver), which are typically found in patients with cirrhosis, a procoagulant imbalance, defined as a partial resistance to the in vitro anticoagulant action of thrombomodulin, can be demonstrated. Whether this in vitro hypercoagulability is truly representative of what occurs in vivo remains to be established. However, the hypothesis that it may have clinical consequences is attractive and deserves attention. The possible consequences that we discuss herein include whether (i) cirrhosis is a condition associated with increased risk of venous thromboembolism or portal vein thrombosis; (ii) the hypercoagulability associated with cirrhosis has any other role outside coagulation (i.e. progression of liver fibrosis); and (iii) anticoagulation should be used in cirrhosis. Although apparently provocative, considering anticoagulation as a therapeutic option in patients with cirrhosis is now supported by a rationale of increasing strength. There may be subgroups of patients who benefit from anticoagulation to treat or prevent thrombosis and to slow hepatic fibrosis. Clinical studies are warranted to explore these therapeutic options.
ER  - 

TY  - JOUR
TI  - HAEMATOLOGY SOCIETY OF AUSTRALIA AND AUSTRALASIAN SOCIETY OF BLOOD TRANSFUSION
JO  - Australian and New Zealand Journal of Medicine
VL  - 15
IS  - 1
SN  - 0004-8291
UR  - https://doi.org/10.1111/j.1445-5994.1985.tb02630.x
DO  - doi:10.1111/j.1445-5994.1985.tb02630.x
SP  - 107
EP  - 122
PY  - 1985
ER  - 

TY  - JOUR
TI  - ACVIM Forum Abstracts
JO  - Journal of Veterinary Internal Medicine
VL  - 21
IS  - 3
SN  - 0891-6640
UR  - https://doi.org/10.1111/j.1939-1676.2007.tb03006.x
DO  - doi:10.1111/j.1939-1676.2007.tb03006.x
SP  - 559
EP  - 670
PY  - 2007
ER  - 

TY  - JOUR
TI  - Abstracts From the Sixth International Conference on Pediatric Mechanical Circulatory Support Systems and Pediatric Cardiopulmonary Perfusion
JO  - Artificial Organs
VL  - 34
IS  - 4
SN  - 0160-564X
UR  - https://doi.org/10.1111/j.1525-1594.2010.01030.x
DO  - doi:10.1111/j.1525-1594.2010.01030.x
SP  - A1
EP  - A25
PY  - 2010
ER  - 

TY  - JOUR
TI  - Speaker abstracts
JO  - Transfusion Alternatives in Transfusion Medicine
VL  - 9
IS  - s1
SN  - 1295-9022
UR  - https://doi.org/10.1111/j.1778-428X.2007.00053.x
DO  - doi:10.1111/j.1778-428X.2007.00053.x
SP  - 1
EP  - 30
PY  - 2007
ER  - 

TY  - JOUR
TI  - Posters
JO  - Diabetic Medicine
VL  - 23
IS  - s4
SN  - 0742-3071
UR  - https://doi.org/10.1111/j.1464-5491.2006.02036_12.x
DO  - doi:10.1111/j.1464-5491.2006.02036_12.x
SP  - 57
EP  - 199
PY  - 2006
ER  - 

TY  - JOUR
TI  - HAEMATOLOGY SOCIETY OF AUSTRALIA AND AUSTRALASIAN SOCIETY OF BLOOD TRANSFUSION
JO  - Australian and New Zealand Journal of Medicine
VL  - 15
IS  - 5
SN  - 0004-8291
UR  - https://doi.org/10.1111/j.1445-5994.1985.tb04256.x
DO  - doi:10.1111/j.1445-5994.1985.tb04256.x
SP  - 107
EP  - 122
PY  - 1985
ER  - 

TY  - JOUR
AU  - Schöfer, Helmut
AU  - Bruns, Roswitha
AU  - Effendy, Isaak
AU  - Hartmann, Martin
AU  - Jappe, Uta
AU  - Plettenberg, Andreas
AU  - Reimann, Holger
AU  - Seifert, Harald
AU  - Shah, Pramod
AU  - Sunderkötter, Cord
AU  - Weberschock, Tobias
AU  - Wichelhaus, Thomas A.
AU  - Nast, Alexander
TI  - Diagnostik und Therapie Staphylococcus aureus bedingter Infektionen der Haut und Schleimhäute
JO  - JDDG: Journal der Deutschen Dermatologischen Gesellschaft
VL  - 9
IS  - 11
SN  - 1610-0379
UR  - https://doi.org/10.1111/j.1610-0387.2011.07786_suppl.x
DO  - doi:10.1111/j.1610-0387.2011.07786_suppl.x
SP  - 953
EP  - 968
PY  - 2011
ER  - 

TY  - JOUR
TI  - 2011 ASPHO Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 56
IS  - 6
SN  - 1545-5009
UR  - https://doi.org/10.1002/pbc.23092
DO  - doi:10.1002/pbc.23092
SP  - 897
EP  - 973
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts cont.
JO  - Clinical Microbiology and Infection
VL  - 10
IS  - s3
SN  - 1198-743X
UR  - https://doi.org/10.1111/j.1469-0691.2004.0902e.x
DO  - doi:10.1111/j.1469-0691.2004.0902e.x
SP  - 366
EP  - 485
PY  - 2004
ER  - 

TY  - JOUR
TI  - Tuesday, 29 August 2017 - Free Communication Sessions 01–24 and Poster Sessions 01–24
JO  - International Dental Journal
JA  - Int Dent J
VL  - 67
IS  - S1
SN  - 0020-6539
UR  - https://doi.org/10.1111/idj.12338
DO  - doi:10.1111/idj.12338
SP  - 2
EP  - 67
PY  - 2017
ER  - 

TY  - JOUR
AU  - Carbone, Federico
AU  - Satta, Nathalie
AU  - Montecucco, Fabrizio
AU  - Virzi, Julien
AU  - Burger, Fabienne
AU  - Roth, Aline
AU  - Roversi, Gloria
AU  - Tamborino, Carmine
AU  - Casetta, Ilaria
AU  - Seraceni, Silva
AU  - Trentini, Alessandro
AU  - Padroni, Marina
AU  - Dallegri, Franco
AU  - Lalive, Patrice H.
AU  - Mach, François
AU  - Fainardi, Enrico
AU  - Vuilleumier, Nicolas
TI  - Anti-ApoA-1 IgG serum levels predict worse poststroke outcomes
JO  - European Journal of Clinical Investigation
JA  - Eur J Clin Invest
VL  - 46
IS  - 9
SN  - 0014-2972
UR  - https://doi.org/10.1111/eci.12664
DO  - doi:10.1111/eci.12664
SP  - 805
EP  - 817
KW  - Acute ischaemic stroke
KW  - anti-ApoA-1 IgG
KW  - computed tomography
KW  - modified Rankin Scale
PY  - 2016
AB  - Abstract Background Autoantibodies to apolipoprotein A-1 (anti-ApoA-1 IgG) were shown to predict major adverse cardiovascular events and promote atherogenesis. However, their potential relationship with clinical disability and ischaemic lesion volume after acute ischaemic stroke (AIS) remains unexplored. Materials and methods We included n = 76 patients admitted for AIS and we investigated whether baseline serum anti-ApoA-1 IgG levels could predict (i) AIS-induced clinical disability [assessed by the modified Rankin Scale (mRS)], and (ii) AIS-related ischaemic lesion volume [assessed by Computed Tomography (CT)]. We also evaluated the possible pro-apoptotic and pro-necrotic effects of anti-ApoA-1 IgG on human astrocytoma cell line (U251) using flow cytometry. Results High levels of anti-ApoA-1 IgG were retrieved in 15·8% (12/76) of patients. Increased baseline levels of anti-ApoA-1 IgG were independently correlated with worse mRS [? = 0·364; P = 0·002; adjusted odds ratio (OR): 1·05 (95% CI 1·01?1·09); P = 0·017] and CT-assessed ischaemic lesion volume [? = 0·333; P < 0·001; adjusted OR: 1·06 (95% CI 1·01?1·12); P = 0·048] at 3 months. No difference in baseline clinical, biochemical and radiological characteristics was observed between patients with high vs. low levels of anti-ApoA-1 IgG. Incubating human astrocytoma cells with anti-ApoA-1 IgG dose dependently induced necrosis and apoptosis of U251 cells in vitro. Conclusion Anti-ApoA-1 IgG serum levels at AIS onset are associated with poorer clinical recovery and worse brain lesion volume 3 months after AIS. These observations could be partly explained by the deleterious effect of anti-ApoA-1 IgG on human brain cell survival in vitro and may have clinical implication in the prediction of poor outcome in AIS.
ER  - 

TY  - JOUR
TI  - American College of Clinical Pharmacy
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 23
IS  - 10
SN  - 0277-0008
UR  - https://doi.org/10.1592/phco.23.12.1327.32698
DO  - doi:10.1592/phco.23.12.1327.32698
SP  - 1327
EP  - 1374
PY  - 2003
ER  - 

TY  - JOUR
TI  - Aspen 6th Clinical Congress Proceedings
JO  - Journal of Parenteral and Enteral Nutrition
JA  - Journal of Parenteral and Enteral Nutrition
VL  - 5
IS  - 6
SN  - 0148-6071
UR  - https://doi.org/10.1177/014860718100500619
DO  - doi:10.1177/014860718100500619
SP  - 552
EP  - 582
PY  - 1981
ER  - 

TY  - JOUR
TI  - ASBMR 22nd annual meeting
JO  - Journal of Bone and Mineral Research
JA  - J Bone Miner Res
VL  - 15
IS  - S1
SN  - 0884-0431
UR  - https://doi.org/10.1002/jbmr.5650150102
DO  - doi:10.1002/jbmr.5650150102
SP  - S1
EP  - S584
PY  - 2000
ER  - 
